Excitatory amino acid receptor antagonists
AssigneeEli Lilly and Company
InventorsThomas John Bleisch, Sandra Ann Filla, Paul Leslie Ornstein
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising compounds or Formula I or Formula II, and methods for treating neurological disorders and neurodegenerative diseases, particularly migraine.
Claims52
A compound of the formula:
- wherein,
- R1 represents hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C10)cycloalkyl, SO2R2, SR2, CH2SR2, (C1-C6)alkyl(C1-C6)alkoxy, aryl, (C1-C6)alkylaryl, (C1-C6)alky(substituted)aryl, or substituted aryl;
- R2 represents (C1-C6)alkyl;
- and
- X represents CH or N;
- or a pharmaceutically acceptable salt or prodrug thereof.
A compound of formula:
- wherein
- R1 represents hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C10)cycloalkyl, SO2R2, SR2, CH2SR2, (C1-C6)alkyl(C1-C6)alkoxy, aryl, (C1-C6)alkylaryl, (C1-C6)alky(substituted)aryl, or substituted aryl;
- R2 represents (C1-C6)alkyl;
- X represents CH or N, and
- R3 and R4 each independently represent hydrogen, (C1-C20)alkyl, (C2-C6)alkenyl, (C1-C6)alkylaryl, (C1-C6)alkyl(C3-C10)cycloalkyl, (C1-C6)alkyl-N,N-C1-C6 dialkylamine, (C1-C6)alkyl-pyrrolidine, (C1-C6)alkyl-piperidine, or (C1-C6)alkyl-morpholine, with the proviso that at least one of R3 or R4 is other than hydrogen;
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- wherein
- Y represents (CH2)n;
- R5 represents aryl, substituted aryl, (C1-C6)alkyl, (C1-C6)alkylaryl, or CF3;
- R6 represents hydrogen, (C1-C6)alkyl, or (C1-C6)alkylaryl;
- and
- n represents 0, 1, 2, or 3;
- or a pharmaceutically acceptable salt or prodrug thereof.
A compound which is (3S, 4aR, 6S, 8aR)-6-[[(2S, 4S)-2-carboxy-4-(N-benzylsulfonamido)-1-pyrrolidinyl]methyl]decahydroisoquinoline-3-carboxylic acid or a pharmaceutically acceptable salt or prodrug thereof.
A compound of the formula:
- wherein
- Y is (CH2)n;
- R3 and R4 each independently represent hydrogen, (C1-C20)alkyl, (C2-C6)alkenyl, (C1-C6)alkylaryl, (C1-C6)alkyl(C3-C10)cycloalkyl, (C1-C6)alkyl-N,N-C1-C6 dialkylamine, (C1-C6)alkyl-pyrrolidine, (C1-C6)alkyl-piperidine, or (C1-C6)alkyl-morpholine, with the proviso that at least one of R3 or R4 is other than hydrogen;
- R5 represents aryl, substituted aryl, (C1-C6)alkyl, (C1-C6)alkylaryl, or CF3;
- R6 represents hydrogen, (C1-C6)alkyl, or (C1-C6)alkylaryl;
- and
- n is 0, 1, 2, 3,
- or a pharmaceutically acceptable salt thereof.
A compound which is Ethyl (3S, 4aR, 6S, 8aR)-6-[[(2S, 4S)-2-ethoxycarbonyl-4-(N-benzylsulfonamido)-1-pyrrolidinyl]methyl]decahydroisoquinoline-3-carboxylate or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.